REGENXBIO is advancing a pipeline of AAV Therapeutics for rare and retinal diseases, including RGX-202 for the treatment of Duchenne, ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy ...

November 12, 2024. More for You ...

AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes AbbVie ...

AbbVie (NYSE:ABBV) and its shareholders were dealt a major setback Monday morning after results from a late-stage trial on ...

US central bank lowered rates by another 25 basis points on Thursday. AbbVie, Chevron, and Elf Beauty could benefit from ...

Chicago, IL – November 8, 2024 – Today, Zacks Investment Ideas feature highlights AbbVie ABBV, Visa V and Comfort Systems USA ...

It also profiles the leading makers of antibody drugs, such as AbbVie and Amgen. The report focuses on how monoclonal ...

Exacerbations of the chronic and progressive inflammatory disease bronchiectasis can impact quality of life. Treatment, based ...

Also, the MassMutual Foundation committed $25 million to expand the reach of nonprofit community development financial institutions, and the Moody Foundation gave $25 million for neuroscience research ...

The global body contouring treatments market growth forecasted to transform from USD 1.46 billion in 2024 to USD 2.58 billion ...